Needham & Company Maintains Buy Rating on salesforce.com (CRM) AFter Rypple Walk Thru
Get Alerts CRM Hot Sheet
Price: $271.92 --0%
Rating Summary:
45 Buy, 19 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 8
Rating Summary:
45 Buy, 19 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 8
Join SI Premium – FREE
Needham & Company reiterated their Buy rating and $160 price target on salesforce.com (NYSE: CRM) after walking thru a demo how Rypple is integrated into salesforce's core offering.
"Our biggest takeaway was not that salesforce is well positioned in next-generation Talent Management, but instead was that salesforce now has an attractive product vehicle to carry Chatter across the enterprise (as opposed to just to sales and service seats)," the analyst notes. "This is important, in our view, because getting Chatter seeded across the enterprise should position salesforce well for some compelling and strategic CIO discussions around broader Force.com and Social Enterprise deployments," they continued.
For an analyst ratings summary and ratings history on salesforce.com click here. For more ratings news on salesforce.com click here.
Shares of salesforce.com closed at $157.18 yesterday.
"Our biggest takeaway was not that salesforce is well positioned in next-generation Talent Management, but instead was that salesforce now has an attractive product vehicle to carry Chatter across the enterprise (as opposed to just to sales and service seats)," the analyst notes. "This is important, in our view, because getting Chatter seeded across the enterprise should position salesforce well for some compelling and strategic CIO discussions around broader Force.com and Social Enterprise deployments," they continued.
For an analyst ratings summary and ratings history on salesforce.com click here. For more ratings news on salesforce.com click here.
Shares of salesforce.com closed at $157.18 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Reiterates Buy Rating on Amazon.com (AMZN), Raises Estimates
- Intra-Cellular Therapies (ITCI) Prices Public Offering of Common Stock
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!